Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

ClinicalTrials.gov ID: NCT02914639

Public ClinicalTrials.gov record NCT02914639. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).

Study identification

NCT ID
NCT02914639
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
OcuTerra Therapeutics, Inc.
Industry
Enrollment
44 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 4, 2016
Primary completion
Jun 25, 2017
Completion
Jun 25, 2017
Last update posted
Jun 6, 2023

2016 – 2017

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
12
Facility City State ZIP Site status
Retinal Research Institute LLC Phoenix Arizona 85014
Retina Consultants of Orange County Fullerton California 92861
Northern California Retina Vitreous Associates Medical Group, Inc Mountain View California 94040
Retina Macula Specialists of Miami, LLC Miami Florida 33126
Center for Retina and Macular Disease Winter Haven Florida 33880
John Kenyon Eye Institute New Albany Indiana 47150
Ophthalmic Consultants of Boston Boston Massachusetts 02114
Black Hills Regional Eye Institute Rapid City South Dakota 57701
West Texas Retina Consultants Abilene Texas 79606
Retina Research Center, PLLC Austin Texas 78705
Texas Retina Associates Fort Worth Texas 76104
Spokane Eye Clinical Research Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02914639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 6, 2023 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02914639 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →